Skip to main content
All lobbying filings

King & Spalding LLP

King & Spalding LLP filed a Q4 termination report for Kaneka Pharma America, LLC on January 19, 2026, reporting $40,000 in lobbying income.

Lobbying for Kaneka Pharma America, LLC · Distributor of life science systems

As filed: KING & SPALDING LLP for KANEKA PHARMA AMERICA, LLC.

All filings by King & Spalding LLP · Everything Kaneka Pharma America, LLC has reported

 Filing · LD-2 quarterly report Q4 termination
Reporting period
4th Quarter 2025
Oct 1 - Dec 31 · Posted Jan 19, 2026
Income
$40,000
What the client paid this registrant for the period.
Client based in
California
Representation ended
Dec 31, 2025
The registrant reported terminating its work for this client.

Official filing document

 Lobbyists on this filing 1
  • SCOTT DZIENGELSKI
    Previously held: Rep. Murphy (PA-18): Leg. Dir. (2015-2017), Sr. Leg. Asst.(2013-2015), Leg. Asst. (2012-2013), Leg. Corr. (2011-2012),Staff Asst. (2010-2011); Energy and Commerce Committee:Staff (2015-2017)

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

 Government bodies contacted 1

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 1
Medicare/Medicaid

Advocacy in support of Medicare Coverage for Dialysis-Related Amyloidosis (DRA) Treatment. H.R. 4055 (119th Cong.).

 Bills named in this filing 1
  • H.R. 4055
    Dialysis-Related Amyloidosis Treatment Act of 2025

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem